Phase I Study in Advanced Cancer Patients of a Diversified Prime-and-Boost Vaccination Protocol Using Recombinant Vaccinia Virus and Recombinant Nonreplicating Avipox Virus to Elicit Anti–Carcinoembryonic Antigen Immune Responses
Top Cited Papers
- 1 December 2000
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 18 (23) , 3964-3973
- https://doi.org/10.1200/jco.2000.18.23.3964
Abstract
PURPOSE: This trial sought to determine, for the first time, the validity in human vaccinations of using two different recombinant vaccines in diversified prime-and-boost regimens to enhance T-cell responses to a tumor antigen. PATIENTS AND METHODS: Eighteen patients with advanced tumors expressing carcinoembryonic antigen (CEA) were randomized to receive either recombinant vaccinia (rV)-CEA followed by three avipox-CEA vaccinations, or avipox-CEA (three times) followed by one rV-CEA vaccination. Subsequent vaccinations in both cohorts were with avipox-CEA. Immunologic monitoring was performed using a CEA peptide and the enzyme-linked immunospot assay for interferon gamma production. RESULTS: rV-CEA followed by avipox-CEA was superior to the reverse order in the generation of CEA-specific T-cell responses. Further increases in CEA-specific T-cell precursors were seen when local granulocyte-macrophage colony-stimulating factor (GM-CSF) and low-dose interleukin (IL)-2 were given with subsequent vaccinations. The treatment was extremely well tolerated. Limited clinical activity was seen using vaccines alone in this patient population. Antibody production against CEA was also observed in some of the treated patients. CONCLUSION: rV-CEA was more effective in its role as a primer of the immune system; avipox-CEA could be given up to eight times with continued increases in CEA T-cell precursors. Future trials should use rV-CEA first followed by avipox-CEA. Vaccines specific to CEA are able to generate CEA-specific T-cell responses in patients without significant toxicity. T-cell responses using vaccines alone may be inadequate to generate significant anticancer objective responses in patients with advanced disease. Cytokines such as GM-CSF and IL-2 may play a key role in generating such responses.Keywords
This publication has 20 references indexed in Scilit:
- COMPARATIVE STUDIES OF THE EFFECTS OF RECOMBINANT GM-CSF AND GM-CSF ADMINISTERED VIA A POXVIRUS TO ENHANCE THE CONCENTRATION OF ANTIGEN- PRESENTING CELLS IN REGIONAL LYMPH NODESCytokine, 2000
- Agonist peptide from a cytotoxic t-lymphocyte epitope of human carcinoembryonic antigen stimulates production of tc1-type cytokines and increases tyrosine phosphorylation more efficiently than cognate peptideInternational Journal of Cancer, 2000
- Phase I Study in Cancer Patients of a Replication-Defective Avipox Recombinant Vaccine That Expresses Human Carcinoembryonic AntigenJournal of Clinical Oncology, 1999
- Quantitative analysis of CEA expression in colorectal adenocarcinoma and serum: Lack of correlationInternational Journal of Cancer, 1997
- Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responsesVaccine, 1997
- Results of a phase I trial of a recombinant vaccinia virus that expresses carcinoembryonic antigen in patients with advanced colorectal cancerAnnals of Surgical Oncology, 1996
- Antitumor Activity and Immune Responses Induced by a Recombinant Carcinoembryonic Antigen-Vaccinia Virus VaccineJNCI Journal of the National Cancer Institute, 1992
- Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion moleculePublished by Elsevier ,1989
- Carcinoembryonic antigens and related glycoproteins molecular aspects and specificityBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1983
- Carcinoembryonic antigen in breast cancer patients: Serum levels and disease progressCancer, 1974